Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
14 Oct 2015
ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer
CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment…
14 Oct 2015
ECC 2015: EUROCARE-5 trial showed large variations in blood cancer survival in Europe
Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least five years after…
14 Oct 2015
ECC 2015: METEOR trial showed cabozantinib improved survival in advanced kidney cancer
METEOR, a phase 3 clinical trial, compared cabozantinib with everolimus for the treatment of patients with advanced clear cell renal cell carcinoma.
14 Oct 2015
The value of an intermediate Recurrence Score® result in the Oncotype DX® Breast Cancer Assay
The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk…
14 Oct 2015
TERRAIN trial of enzalutamide versus bicalutamide for advanced prostate cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC…
14 Oct 2015
Assessing the eligibility of a breast cancer patient for genomic testing
Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or…
14 Oct 2015
Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…
14 Oct 2015
Experience of the Oncotype DX® Breast Cancer Assay in the clinic
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…
12 Oct 2015
European Liver Patients’ Association (ELPA) Launches Call to Action Report for the Treatment of Hepatic Encephalopathy
BRUSSELS, BELGIUM, 12 October 2015, 18:30 CET – ELPA today launched a new call to action report ‘Time to DeLiver: Getting a Grip on HE’ at the…
12 Oct 2015
Exercise and Stop Smoking to Improve Depression after Heart Attack
Sophia Antipolis, 10 October 2015: Exercise and stop smoking to improve depression after a heart attack, the European Society of Cardiology (ESC) urged …
←
1
2
3
…
92
93
94
95
96
97
98
…
151
152
153
→